Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 47

Total 47 documents found.

  •  
  • 1 1 Takeda Pharmaceutical Company Limited Management PolicyManagement Policy Growing Toward aGrowing Toward a ""WorldWorld--Class PharmaceuticalClass Pharmaceutical CompanyCompany"" based on Takedabased on Takeda--ismism President Yasuchika Hasegawa September 28, 2007 2 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited Performance of TakedaPerformance of Takeda 0 200 400 600 800 1,000 1,200 1,400 0 100 200 300 400 500 600 91 92 93 94 95 96 97 98 99 00 01 02 03 04 07(E) Net Sales Operating Income Ordinary Income 05 To achieve consecutive increased income for 17 years 90 06 (Billions of Yen) (Billions of Yen) 2 3 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited Sales of international strategic productsSales of international strategic products * including affiliated companies 0 250 500 2003 2004 2005 '06 184.8 '06 400.7 '06 206.9 '06 337.0 2006 (Billions of Yen) Leuprorelin Lansoprazole Candesartan Pioglitazon 4 Takeda Pharmaceutical Company LimitedTakeda Pharm
  • ANNUALREPORT2009TakedaPharmaceuticalCompanyLimited Annual Report 2009 Our Contribution to Financial and Social Responsibility Editorial Policy Takeda integrates its annual report and CSR report into a single publication with a mind to give readers a complete understanding of how our business operations are guided by Takeda-ism and other elements of our corporate philosophy. Contributes to the Health of Individuals Takeda has been supplying pharmaceuticals for more than 220 years while never forgetting the importance of protecting and preserving life. Over the years, we have developed a strong commitment to the highest ethical standards and strong sense of mission. As our operations became global in scale, demands concerning corporate social responsibility (CSR) increased. We believe that developing superior pharmaceutical products in accordance with the principles of Takeda-ism is the essence of CSR for the Takeda Group. Due to this strong link between our business activities and CSR, since fiscal 2006, Take
  • 30 The R&D pipeline represents ethical drugs under development, from the start of research to approval and launch. Clinical trials are conducted on humans for drugs for which basic research and non-clinical trials have been completed. Newly developed drugs that have undergone efficacy and safety evaluation via three phases of clinical trials are launched onto the market as new drugs after approval by the regulatory authorities. Conducted using a small group of healthy adult volunteers in order to evaluate safety and ADME (Absorption, Distribution, Metabolism, Excretion) of the drug. R&D Pipeline Major Pipeline Drugs Offering Potential as Next-Generation Core Products Basic research / Non-clinical trials Clinical trials Conducted using a small group of patient volunteers in order to evaluate safety, efficacy, dosage, and administration methods. Conducted using a large number of patient volunteers in order to evaluate safety and efficacy in comparison to medications used previously. Application PhaseI PhaseII
  • XOMA and Takeda Expand Collaboration February 10, 2009
  • BERKELEY, Calif. and Osaka, Japan, February 10, 2009 -- XOMA Ltd. (Nasdaq:XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have expanded their existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. XOMA will receive a $29 million expansion fee and may receive potential milestones and royalties on antibody products. XOMA may incur an estimated $7.5 million for taxes and other costs related to the expanded collaboration.
  • Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics May 27, 2008
  • CAMBRIDGE, Mass., USA and OSAKA, Japan, May 27, 2008 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas. This landmark alliance is the first major RNAi therapeutics partnership between a Japanese pharmaceutical company and a U.S. biotechnology company, representing a new frontier in the advancement of RNAi therapeutics to patients on a global basis.
  • 1 Takeda Pharmaceutical Company Limited First Quarter Financial ResultsFirst Quarter Financial Results for Fiscal 2007for Fiscal 2007 Conference Call July 31, 2007Conference Call July 31, 2007 Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited Consolidated ResultsConsolidated Results First Quarter of Fiscal 2007First Quarter of Fiscal 2007 Hiroshi Takahara Corporate Officer, General Manager Finance & Accounting Department Takeda Pharmaceutical Company Limited 2 3 Takeda Pharmaceutical Company Limited Outline of Consolidated ResultsOutline of Consolidated Results '06 1Q '07 1Q Year-on-year change billions of yen billions of yen billions of yen <%> Net sales 334.3 366.3 32.0 < 9.6 > Operating income 132.1 153.1 21.0 < 15.9 > Ordinary income 162.6 190.4 27.9 < 17.2 > (Extraordinary income) 【38.2 】 【29.1 】 【- 9.1 】 < - 23.8 > Net income 124.6 131.0 6.4 < 5.1 > R&D expenses 50.6 47.3 - 3.3 < - 6.5 > E P S 141.30 yen 152.74 yen 11.44 yen < 8.1 >
  • XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development February 28, 2007
  • Berkeley, CA, and Osaka, JAPAN - February 28, 2007 - XOMA Ltd. (Nasdaq: XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have amended their existing agreement to increase the number of potential therapeutic antibody programs under the collaboration initiated in November of 2006.With this expansion, XOMA estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million before royalties over the life of the agreement. Since entering the original agreement four months ago, XOMA has receivedor is otherwise due approximately $8 million as various collaboration-related payments.
  • 1 Takeda Pharmaceutical Company Limited President Yasuchika Hasegawa November 7, 2006 Management PolicyManagement Policy First half in Fiscal 2006 2 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited 2006-2010 Medium-Term Management Plan Approaches toward lean andApproaches toward lean and solid structuresolid structure 9595--0000 PlanPlan 0101--0505 PlanPlan 〜〜 Growth Toward aGrowth Toward a ""WorldWorld--Class PharmaceuticalClass Pharmaceutical Company with Japanese Origin, as based on TakedaCompany with Japanese Origin, as based on Takeda--ismism""〜〜20062006--20102010 MediumMedium--TermTerm Management PlanManagement Plan New growth stage toward aNew growth stage toward a ""WorldWorld--class pharmaceuticalclass pharmaceutical companycompany"" 3 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited 2006 2010 Medium-Term Management Plan Financial Goals Sales: mid-single digit growth R&D: high-single digit increase Net income: low-single digit growth EPS: more
  • FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000066 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2039 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/english/financial/index.html 2006-2010 Medium-Term Management Plan 〜 Growth toward a World-class Pharmaceutical Company with Japanese Origin 〜 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect sales of in-house ethical products of 2 trillion yen in fiscal 2015 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market function in each region with self-sustaining
  • Date Summary 3-Apr-06 Takeda Enters into Joint Research Agreement with Arius on Functional Antibodies in Cancer Field 3-Apr-06 Takeda Submits New Drug Application for Extended Release Type 2 Diabetes Medication, ACTOplus met(pioglitazone HCl and metformin HCl) 3-Apr-06 Transfer of Shares of Mitsui Takeda Chemicals, Inc. from Takeda to Mitsui Chemicals 20-Apr-06 Takeda Announces Conclusion of Successful ACTOS (pioglitazone HCl) Marketing Collaboration in the United States 26-Apr-06 AMITIZA(lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation, Launches in the United States Novel mechanism of action provides effective and predictable relief for adults living with chronic idiopathic constipation 11-May-06 Takeda Announces "2006-2010 Medium-Term Management Plan" - Growth toward a World-class Pharmaceutical Company with Japanese Origin - 11-May-06 Notice regarding Acquisition of the Company's own shares 11-May-06 Takeda to Change the Structure of Consol
  • 1 Takeda Pharmaceutical Company Limited Kiyoshi Kitazawa Managing Director, General Manager Strategic Product Planning Dept. November 7, 2006 MM PP DD RR AA PP R&D pipeline Update First half in Fiscal 2006 2 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited Core Therapeutic AreasCore Therapeutic Areas Franchise I: Life style-related diseases Franchise II :Oncology & Urology diseases Franchise III:CNS, bone/joint diseases Franchise IV:Gastroenterology diseases 3 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited ○Fixed combination with diuretic (Jpn)TCV-116 ApprovalNDAPhIIIPhIIIndications or formulationsProject ○Diabetes mellitus (US,EU)SYR-322 Combination drug of ACTOS/SU (EU) AD-4833SU (Tandemact) ○Delay in progression of Atherosclerosis (US)AD-4833 ○Combination drug of ACTOS/Metformin XT(US)AD-4833XT ○Impaired Glucose Tolerance (Jpn)AO-128 ○Combination drug of ACTOS/Metformin (EU) AD-4833MET (Competact) ○Combination drug of ACTOS/SU (US) AD-4833SU (Du

Pages:[1] [2] [3]   Next

Page Top